MiMedx Group Inc (MDXG) : Traders are bullish on MiMedx Group Inc (MDXG) as it has outperformed the S&P 500 by a wide margin of 26.95% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.95%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.53% in the last 1 week, and is up 24.38% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 17.6% and the 50-Day Moving Average is 17.86%.The 200 Day SMA reached 12.65% MiMedx Group, Inc. is up 21.55% in the last 3-month period. Year-to-Date the stock performance stands at -3.09%.
MiMedx Group Inc (MDXG) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $13 and the lowest price target forecast is $9. The average forecast of all the analysts is $11.6 and the expected standard deviation is $1.52.
For the current week, the company shares have a recommendation consensus of Buy. MiMedx Group Inc (NASDAQ:MDXG): The stock opened at $9 and touched an intraday high of $9.13 on Friday. During the day, the stock corrected to an intraday low of $8.86, however, the bulls stepped in and pushed the price higher to close in the green at $9.08 with a gain of 1.00% for the day. The total traded volume for the day was 1,584,572. The stock had closed at $9.08 in the previous trading session.
MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.